Tricida, Inc. (TCDA)
Stock Price:
$9.01 USD
-0.18 (-1.96%)
Updated Oct 19, 2020 4:00 PM EDT - Market closed
Key Info
| Market Cap |
450.94M |
| Revenue (ttm) |
n/a |
| Net Income (ttm) |
-234.57M |
| Shares Out |
50.05M |
| EPS (ttm) |
-4.72 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Oct 19, 2020 |
| Last Price |
$9.01 |
| Previous Close |
$9.19 |
| Change ($) |
-0.18 |
| Change (%) |
-1.96% |
| Day's Open |
9.17 |
| Day's Range |
8.97 - 9.29 |
| Day's Volume |
277,864 |
| 52-Week Range |
8.50 - 44.30 |
More Stats
| Market Cap |
450.94M |
| Enterprise Value |
262.39M |
| Earnings Date (est) |
Nov 5, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
50.05M |
| Float |
38.98M |
| EPS (basic) |
-4.73 |
| EPS (diluted) |
-4.72 |
| FCF / Share |
-4.05 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
3.39M |
| Short Ratio |
5.44 |
| Short % of Float |
8.69% |
| Beta |
1.06 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
n/a |
| PB Ratio |
1.99 |
| Revenue |
n/a |
| Operating Income |
-233.29M |
| Net Income |
-234.57M |
| Free Cash Flow |
-202.30M |
| Net Cash |
188.55M |
| Net Cash / Share |
3.77 |
| Gross Margin |
n/a |
| Operating Margin |
n/a |
| Profit Margin |
n/a |
| FCF Margin |
n/a |
| ROA |
-33.50% |
| ROE |
-81.19% |
| ROIC |
-54.30% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (4)
| Buy |
2 |
| Overweight |
0 |
| Hold |
1 |
| Underweight |
0 |
| Sell |
1 |
Analyst Consensus: Overweight
Price Target
$19.50*
(116.43% upside)
Low
8.00
Current: $9.01
High
40.00
Target: 19.50
*Average 12-month price target from 4 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 |
|---|
| Revenue | - | - | - | - |
| Operating Income | -179 | -104 | -47.12 | -27.18 |
| Net Income | -177 | -103 | -41.29 | -28.65 |
| Shares Outstanding | 47.52 | 22.15 | 2.14 | 1.83 |
| Earnings Per Share | -3.72 | -4.64 | -19.32 | -15.69 |
| Operating Cash Flow | -130 | -94.86 | -40.40 | -23.12 |
| Capital Expenditures | -1.42 | -0.86 | -1.00 | -0.25 |
| Free Cash Flow | -131 | -95.71 | -41.41 | -23.36 |
| Cash & Equivalents | 308 | 241 | 67.51 | 26.45 |
| Total Debt | 68.23 | 38.07 | - | - |
| Net Cash / Debt | 240 | 203 | 67.51 | 26.45 |
| Assets | 372 | 248 | 70.57 | 27.68 |
| Liabilities | 108 | 53.32 | 11.55 | 8.43 |
| Book Value | 264 | 195 | -88.04 | -47.63 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Tricida, Inc. |
| Country |
United States |
| Employees |
195 |
| CEO |
Gerrit Klaerner |
Stock Information
| Ticker Symbol |
TCDA |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Drug Manufacturers—Specialty & Generic |
| Unique Identifier |
NASDAQ: TCDA |
| IPO Date |
June 28, 2018 |
Description
Tricida, a pharmaceutical company, focuses on the development and commercialization of its drug candidate, TRC101, a non-absorbed, orally-administered polymer designed as a potential treatment for metabolic acidosis in patients with chronic kidney disease (CKD). The company has completed a Phase 3, double-blind, placebo-controlled trial of TRC101 in patients with CKD and metabolic acidosis. Tricida, Inc. was founded in 2013 and is headquartered in South San Francisco, California.